Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer
Aachen, Germany, 30 September 2024 – Grünenthal announced today that Jan Adams, M.D., currently Chief Scientific Officer (CSO) and member of the Corporate Executive Board, will assume the role of Chief Commercial Officer (CCO) effective 1 October 2024. Prior to his role as CSO, he was Head of Strategy and Portfolio at Grünenthal.
Jan Adams has over two decades of experience in the pharmaceutical and healthcare industry. Since joining Grünenthal in 2017, he has been key in driving the company's transformational journey. Under his leadership, Grünenthal successfully built a state-of-the-art R&D organisation, redefined its R&D strategy, and built an industry-leading pipeline focused on delivering innovative treatments for acute and chronic pain. Before assuming the role of CSO, he served as Head of Strategy and Portfolio, working at the interface between Strategy, R&D, and Commercial. His role was instrumental in several successful M&A projects and Grünenthal’s entry into the U.S. market. Before joining Grünenthal, he held positions with increasing responsibilities at Takeda, McKinsey & Company, and Novartis. Jan Adams started his career as a resident in cardiology. He is a Medical Doctor by training, married, and has two children.
Jan Adams succeeds Janneke van der Kamp, who will leave Grünenthal to pursue an opportunity outside the company.
Kontakter
Florian DieckmannHead of Global Corporate Affairs & Communication
Tlf:+49 241 569-2555florian.dieckmann@grunenthal.comBilleder
About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of €1.8 billion.
More information: https://www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group
Instagram: grunenthal
Følg pressemeddelelser fra Grünenthal Group
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Grünenthal Group
Grünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik®22.7.2024 09:56:23 CEST | Press release
Grünenthal acquires the pharmaceutical company Valinor Pharma, further strengthening Grünenthal’s footprint in the United States. With the acquisition, Grünenthal becomes the global owner of Movantik® / Moventig® (naloxegol). Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly strengthening its profitability.
Grünenthal announces significant investments in its Latin America production sites, further securing reliable medicine supply for patients17.7.2024 10:30:02 CEST | Press release
Investment of more than €80 million to modernise Latin American production sites. In Santiago de Chile, a 3,500-square-metre solids plant has been completely refurbished, creating a world-class manufacturing facility with a production capacity of 1.8 billion tablets annually. In Quito, Ecuador, a new 1,800-square-metre plant will enable the production of 300 million high-quality tablets annually for pain patients in 17 European countries.
Grünenthal’s resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee22.5.2023 10:38:59 CEST | Press release
Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid therapy, in adults with pain associated with knee osteoarthritis. The U.S. Food and Drug Administration’s Breakthrough Therapy Designation process aims to expedite the development of investigational medicines intended to treat severe conditions and where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on clinically significant endpoints. Aachen, Germany, 22 May 2023 – Grünenthal today announced that its investigational non-opioid medicine resiniferatoxin (RTX), currently undergoing clinical Phase III development, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for pain associated with osteoa
Grünenthal and King’s College London collaborate to develop human induced pluripotent stem cell-based microfluidic cultures for pain research27.4.2023 08:00:00 CEST | Press release
Dr Ramin Raouf from King's College London and Grünenthal strive to develop reliable microfluidic culture models relevant for pain research based on human induced pluripotent stem cell-derived neurons Grünenthal has expertise in developing human induced pluripotent stem cells towards sensory neurones and will support the lab of Dr Raouf with a total consideration of more than £350.000. Aachen, Germany and London, England, 27 April 2023 – Grünenthal and King’s College London announced a 24 months collaboration to develop microfluidic culture (MFC) models based on human induced pluripotent stem cells (iPSCs) and tailored to pain research. The collaboration aims to build on Dr Ramin Raouf’s pioneering work on MFCs by establishing models using human iPSC-derived neurons that closely mimic the functionality of human nociceptive neurones. Grünenthal will support the lab of Dr Raouf with its competencies in characterising human iPSCs and a total consideration of more than £350.000. The collabo
Janneke van der Kamp starts as new Chief Commercial Officer at Grünenthal1.3.2023 11:19:06 CET | Pressemeddelelse
Janneke van der Kamp has today assumed her role as the new Chief Commercial Officer (CCO) of Grünenthal. She joins Grünenthal’s executive board and is responsible for the entire Global Commercial Organisation.